Tags

Type your tag names separated by a space and hit enter

Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
Contraception. 1985 Apr; 31(4):395-408.C

Abstract

Changes in serum lipid and lipoprotein levels were evaluated in a randomized prospective study conducted in matched healthy young women before and after 6 months' use of three oral contraceptives (OCs): Trigynon (preparation A, n = 13), a triphasic OC containing low doses of ethinylestradiol (EE) and levonorgestrel (LNG); Marvelon (preparation B, n = 14), a monophasic OC containing low doses of EE + Desogestrel (DOG, a new progestogen derived from LNG); and Ovidol (preparation C, n = 11), a sequential OC containing higher doses (50 micrograms) of EE + DOG. After 6 months of use, total triglyceride levels were non-significantly increased by preparations A (+ 29% from basal values) and B (+21%), and very significantly increased by preparation C (+90%). Total cholesterol and phospholipids were unchanged by preparations A and B, whereas phospholipids were significantly increased by preparation C. However, HDL-cholesterol, LDL-cholesterol and their epidemiologically important ratios (HDL-chol:total-chol; LDL-chol:HDL-chol) were kept unchanged by all preparations tested. Apolipoprotein A-1 (Apo A-1) was slightly but significantly increased by all three preparations whereas apolipoprotein B (Apo B) was significantly decreased by preparation B. All ratios Apo A-1:Apo B were accordingly ("favorably") increased, especially during treatment with preparation B. In conclusion, the triphasic OC containing low doses of LNG does not induce obvious, clinically significant, alterations of lipid metabolism, and it is also the case for the low-dose monophasic combination of EE + DOG. The higher-dose sequential preparation of EE + DOG behaves as a more estrogenic compound, increasing total triglyceride concentrations above the normal range.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

3159546

Citation

Gaspard, U J., et al. "Serum Lipid and Lipoprotein Changes Induced By New Oral Contraceptives Containing Ethinylestradiol Plus Levonorgestrel or Desogestrel." Contraception, vol. 31, no. 4, 1985, pp. 395-408.
Gaspard UJ, Buret J, Gillain D, et al. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Contraception. 1985;31(4):395-408.
Gaspard, U. J., Buret, J., Gillain, D., Romus, M. A., & Lambotte, R. (1985). Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Contraception, 31(4), 395-408.
Gaspard UJ, et al. Serum Lipid and Lipoprotein Changes Induced By New Oral Contraceptives Containing Ethinylestradiol Plus Levonorgestrel or Desogestrel. Contraception. 1985;31(4):395-408. PubMed PMID: 3159546.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. AU - Gaspard,U J, AU - Buret,J, AU - Gillain,D, AU - Romus,M A, AU - Lambotte,R, PY - 1985/4/1/pubmed PY - 1985/4/1/medline PY - 1985/4/1/entrez KW - Age Factors KW - Anthropometry KW - Biology KW - Body Weight KW - Contraception KW - Contraceptive Agents, Estrogen KW - Contraceptive Agents, Female--side effects KW - Contraceptive Agents, Progestin KW - Contraceptive Agents--side effects KW - Contraceptive Methods--side effects KW - Data Analysis KW - Diseases KW - Endocrine System KW - Ethinyl Estradiol KW - Family Planning KW - Hormones KW - Levonorgestrel KW - Lipid Metabolic Effects--analysis KW - Lipid Metabolic Effects--changes KW - Lipids KW - Metabolic Effects KW - Oral Contraceptives, Combined--side effects KW - Oral Contraceptives, Phasic--side effects KW - Oral Contraceptives--side effects KW - Physiology KW - Population Characteristics KW - Prospective Studies KW - Reproductive Control Agents KW - Research Methodology KW - Studies SP - 395 EP - 408 JF - Contraception JO - Contraception VL - 31 IS - 4 N2 - Changes in serum lipid and lipoprotein levels were evaluated in a randomized prospective study conducted in matched healthy young women before and after 6 months' use of three oral contraceptives (OCs): Trigynon (preparation A, n = 13), a triphasic OC containing low doses of ethinylestradiol (EE) and levonorgestrel (LNG); Marvelon (preparation B, n = 14), a monophasic OC containing low doses of EE + Desogestrel (DOG, a new progestogen derived from LNG); and Ovidol (preparation C, n = 11), a sequential OC containing higher doses (50 micrograms) of EE + DOG. After 6 months of use, total triglyceride levels were non-significantly increased by preparations A (+ 29% from basal values) and B (+21%), and very significantly increased by preparation C (+90%). Total cholesterol and phospholipids were unchanged by preparations A and B, whereas phospholipids were significantly increased by preparation C. However, HDL-cholesterol, LDL-cholesterol and their epidemiologically important ratios (HDL-chol:total-chol; LDL-chol:HDL-chol) were kept unchanged by all preparations tested. Apolipoprotein A-1 (Apo A-1) was slightly but significantly increased by all three preparations whereas apolipoprotein B (Apo B) was significantly decreased by preparation B. All ratios Apo A-1:Apo B were accordingly ("favorably") increased, especially during treatment with preparation B. In conclusion, the triphasic OC containing low doses of LNG does not induce obvious, clinically significant, alterations of lipid metabolism, and it is also the case for the low-dose monophasic combination of EE + DOG. The higher-dose sequential preparation of EE + DOG behaves as a more estrogenic compound, increasing total triglyceride concentrations above the normal range. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/3159546/Serum_lipid_and_lipoprotein_changes_induced_by_new_oral_contraceptives_containing_ethinylestradiol_plus_levonorgestrel_or_desogestrel_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0010-7824(85)90006-X DB - PRIME DP - Unbound Medicine ER -